Cracking the code: how will the Human Genome Project affect life as we know it?

---

• 1.
• Wells HG. The Island of Dr Moreau. London: Heinemann, 1960.
• 2.
• Cardon LR, Watkins H. Waiting for the working draft from the humangenome project. BMJ 2000; 320: 1223-1224.
• 3.
• Zimmern RL. The human genome project: A false dawn? BMJ1999; 319: 1282.
• 4.
• van Ommen GJB, E Bakker, den Dunnen JT. The Human Genome Project andthe future of diagnostics, treatment, and prevention.Lancet 1999; 354 (suppl 1): 5-10.
• 5.
• Barroso I, Gurnell M, Crowley VEF, et al. Dominant negativemutations in human PPARgamma associated with severe insulinresistance, diabetes mellitus and hypertension. Nature1999; 402: 880-883.
• 6.
• Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a commonvariant of the cholesteryl ester transfer protein gene in theprogression of coronary atherosclerosis. N Engl J Med 1998;338: 86-93.
• 7.
• Nebert DW. Polymorphisms in drug-metabolising enzymes: What istheir clinical relevance and why do they exist? Am J Hum Genet1997; 60: 265-271.
• 8.
• Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-veinthrombosis in carriers of a prothrombin-gene mutation and in users oforal contraceptives. N Engl J Med 1998; 338: 1793-1797.
• 9.
• Trent RJA. Milestones of the Human Genome Project: genesis to postgenome. Med J Aust 2000; 173: 591-594.
• 10.
• Sutherland GR. Just how long can we live? Med J Aust 2000;173: 594-596.
• 11.
• Hassan R. Social consequences of manufactured longevity. MedJ Aust 2000; 173: 601-603.
• 12.
• Kirby MD. The Human Genome Project in the dock. Med J Aust2000; 173: 599-600.
• 13.
• Stott Despoja N. The Human Genome Project: how do we protectAustralians? Med J Aust 2000; 173: 596-598.